0001213900-22-064061.txt : 20221116 0001213900-22-064061.hdr.sgml : 20221116 20221014150311 ACCESSION NUMBER: 0001213900-22-064061 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20221014 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 CORRESP 1 filename1.htm

INMED PHARMACEUTICALS INC.
Suite 310 - 815 West Hastings Street

Vancouver, British Columbia, Canada

V6C 1B4

VIA EDGAR

October 14, 2022

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Re: InMed Pharmaceuticals Inc.

Acceleration Request for Registration Statement on Form S-1

Filed October 12, 2022

File No. 333-267831

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to October 18, 2022, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable.

If you have any questions regarding this request, please contact Brian Fenske of Norton Rose Fulbright US LLP at (713) 651 5557.

	Sincerely,

	INMED PHARMACEUTICALS INC.

	/s/ Eric A. Adams
	Eric A. Adams
	President and Chief Executive Officer

cc: Brenda Edwards, InMed Pharmaceuticals Inc.

Brian Fenske, Norton Rose Fulbright US LLP